Effect of Serotonin Level on Constipation Caused by Chemotherapy in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

University of Minnesota (UMN)

Status: Terminated

Conditions: Fallopian Tube Cancer; Bowel Obstruction; Peritoneal Cavity Cancer; Ovarian Cancer; Constipation

Study type: Observational

Funder types: Other

Identifiers

NCT00536523

2007NT031

WCC-52 (Other Identifier)

Details and patient eligibility

About

RATIONALE: Gathering information about changes in serotonin levels in patients undergoing chemotherapy for ovarian cancer, fallopian tube cancer, or primary peritoneal cancer may help doctors learn more about constipation caused by chemotherapy.

PURPOSE: This clinical trial is studying how blood levels of serotonin effect constipation caused by chemotherapy in patients with newly diagnosed ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Full description

OBJECTIVES:

• To determine if there are any alterations in serotonin levels in patients undergoing chemotherapy for ovarian, fallopian tube, or primary peritoneal cancer and if this is associated with increased constipation.

OUTLINE: Patients undergo blood sample collection prior to beginning of planned postoperative chemotherapy, after 3 and 6 courses of chemotherapy, and at the 3-month surveillance visit. Patients also complete a bowel function questionnaire at these time points.

Enrollment: 13 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer
• Planned to undergo 6 courses of a taxane and platinum-containing regimen

Exclusion criteria

• Ovarian low malignant potential tumor
• History of constipation or irritable bowel syndrome
• History of colorectal cancer
• Prior bowel resection at time of staging/cytoreductive surgery
• Prior abdominal-pelvic radiation
• Prior bowel surgery

Trial design

13 participants in 1 patient group

Patients Receiving Chemotherapy

Description:

Patients with newly diagnosed ovarian, fallopian tube or primary peritoneal cancer for which 6 cycles of a taxane and platinum containing regimen is planned